SetPoint Medical Expands RA Neuroimmune Therapy Access
Atlantic City, New Jersey, U.S., September 28, 2026 SetPoint Medical has announced an important clinical-access milestone following the completion...
rheumatoid arthritis
Advertisement
Alfasigma Gains Positive CHMP Opinion for Filgotinib in axSpA
MILAN, Italy — September 18, 2026 Alfasigma announced that the Committee for Medicinal Products for Human Use (CHMP) of...
Dualitas Therapeutics and Roche Launch $1B Bispecific Collaboration
SOUTH SAN FRANCISCO, Calif. — September 17, 2026 Dualitas Therapeutics announced a research collaboration and license agreement with Roche...
SetPoint Medical Expands RA Neuroimmune Therapy in Oregon
Valencia, California, USA, September 16, 2026 SetPoint Medical announced that Oregon Health & Science University (OHSU) has become the...
Nkarta to Present Initial NKX019 Autoimmune Data at ACR 2026
SOUTH SAN FRANCISCO, California — September 8, 2026 Nkarta, Inc. announced that three scientific presentations featuring NKX019 have been...
Advertisements
Artiva Biotherapeutics Advances AlloNK Toward Phase 3 in RA
SAN DIEGO, California — September 8, 2026 Artiva Biotherapeutics, Inc. announced planned clinical data disclosures and development milestones for...
SynAct Pharma Advances Resomelagon Toward Phase 3 in RA
Lund, Sweden, September 7, 2026 SynAct Pharma AB has reported further analyses from its Phase 2b ADVANCE clinical trial...
Spyre Reports SPY072 Rheumatoid Arthritis Phase 2 Results
WALTHAM, Mass. — August 25, 2026 Spyre Therapeutics, Inc. announced topline results from the rheumatoid arthritis (RA) sub-study of...
Neutrolis Reports First Human NET-Degrading Therapy Evidence
CAMBRIDGE, Mass., July 15, 2026 Neutrolis announced the publication of a clinical report in the New England Journal of...
Keenova Publishes New Real-World Acthar Gel Autoimmune Data
DUBLIN, Ireland, July 13, 2026 Keenova Therapeutics plc has announced the publication of a new peer-reviewed real-world evidence study...
Advertisement
